Literature DB >> 34645612

Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer.

Rajendra Kumar1, Janet Mendonca1, Olutosin Owoyemi1, Kavya Boyapati1, Naiju Thomas1, Suthicha Kanacharoen1, Max Coffey1, Deven Topiwala1, Carolina Gomes1, Busra Ozbek1, Tracy Jones1, Marc Rosen1, Liang Dong1, Sadie Wiens2, W Nathaniel Brennen1, John T Isaacs1, Angelo M De Marzo1, Mark C Markowski1, Emmanuel S Antonarakis1, David Z Qian2, Kenneth J Pienta1, Drew M Pardoll1, Michael A Carducci1, Samuel R Denmeade1, Sushant K Kachhap3.   

Abstract

The discovery that androgens play an important role in the progression of prostate cancer led to the development of androgen deprivation therapy (ADT) as a first line of treatment. However, paradoxical growth inhibition has been observed in a subset of prostate cancer upon administration of supraphysiologic levels of testosterone (SupraT), both experimentally and clinically. Here we report that SupraT activates cytoplasmic nucleic acid sensors and induces growth inhibition of SupraT-sensitive prostate cancer cells. This was initiated by the induction of two parallel autophagy-mediated processes, namely, ferritinophagy and nucleophagy. Consequently, autophagosomal DNA activated nucleic acid sensors converge on NFκB to drive immune signaling pathways. Chemokines and cytokines secreted by the tumor cells in response to SupraT resulted in increased migration of cytotoxic immune cells to tumor beds in xenograft models and patient tumors. Collectively, these findings indicate that SupraT may inhibit a subset of prostate cancer by activating nucleic acid sensors and downstream immune signaling. SIGNIFICANCE: This study demonstrates that supraphysiologic testosterone induces two parallel autophagy-mediated processes, ferritinophagy and nucleophagy, which then activate nucleic acid sensors to drive immune signaling pathways in prostate cancer. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34645612      PMCID: PMC8639619          DOI: 10.1158/0008-5472.CAN-20-3607

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  53 in total

1.  Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Authors:  Michael T Schweizer; Emmanuel S Antonarakis; Hao Wang; A Seun Ajiboye; Avery Spitz; Haiyi Cao; Jun Luo; Michael C Haffner; Srinivasan Yegnasubramanian; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Samuel R Denmeade
Journal:  Sci Transl Med       Date:  2015-01-07       Impact factor: 17.956

Review 2.  STING and the innate immune response to nucleic acids in the cytosol.

Authors:  Dara L Burdette; Russell E Vance
Journal:  Nat Immunol       Date:  2013-01       Impact factor: 25.606

3.  Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP-AMP.

Authors:  Guijun Shang; Conggang Zhang; Zhijian J Chen; Xiao-Chen Bai; Xuewu Zhang
Journal:  Nature       Date:  2019-03-06       Impact factor: 49.962

Review 4.  Increased lipogenesis in cancer cells: new players, novel targets.

Authors:  Johannes V Swinnen; Koen Brusselmans; Guido Verhoeven
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2006-07       Impact factor: 4.294

Review 5.  Lipids and prostate cancer.

Authors:  Janel Suburu; Yong Q Chen
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-04-05       Impact factor: 3.072

6.  A new human prostate carcinoma cell line, 22Rv1.

Authors:  R M Sramkoski; T G Pretlow; J M Giaconia; T P Pretlow; S Schwartz; M S Sy; S R Marengo; J S Rhim; D Zhang; J W Jacobberger
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Jul-Aug       Impact factor: 2.416

7.  Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Authors:  Payel Chatterjee; Michael T Schweizer; Jared M Lucas; Ilsa Coleman; Michael D Nyquist; Sander B Frank; Robin Tharakan; Elahe Mostaghel; Jun Luo; Colin C Pritchard; Hung-Ming Lam; Eva Corey; Emmanuel S Antonarakis; Samuel R Denmeade; Peter S Nelson
Journal:  J Clin Invest       Date:  2019-07-16       Impact factor: 14.808

Review 8.  Treatment strategies for DNA repair-deficient prostate cancer.

Authors:  Benjamin A Teply; Emmanuel S Antonarakis
Journal:  Expert Rev Clin Pharmacol       Date:  2017-06-12       Impact factor: 5.045

9.  Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer.

Authors:  Benjamin A Teply; Sushant Kachhap; Mario A Eisenberger; Samuel R Denmeade
Journal:  Eur Urol       Date:  2016-09-29       Impact factor: 20.096

10.  Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Authors:  Benjamin A Teply; Hao Wang; Brandon Luber; Rana Sullivan; Irina Rifkind; Ashley Bruns; Avery Spitz; Morgan DeCarli; Victoria Sinibaldi; Caroline F Pratz; Changxue Lu; John L Silberstein; Jun Luo; Michael T Schweizer; Charles G Drake; Michael A Carducci; Channing J Paller; Emmanuel S Antonarakis; Mario A Eisenberger; Samuel R Denmeade
Journal:  Lancet Oncol       Date:  2017-12-14       Impact factor: 41.316

View more
  7 in total

1.  Mechanisms of the Supra-T paradox.

Authors:  Louise Stone
Journal:  Nat Rev Urol       Date:  2021-12       Impact factor: 14.432

Review 2.  The role of ferroptosis in prostate cancer: a novel therapeutic strategy.

Authors:  Yue Wang; Yifan Ma; Kui Jiang
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-09-02       Impact factor: 5.455

Review 3.  Tumor Microenvironment: Lactic Acid Promotes Tumor Development.

Authors:  Yuting Gao; Hao Zhou; Gege Liu; Junlu Wu; Yi Yuan; Anquan Shang
Journal:  J Immunol Res       Date:  2022-06-12       Impact factor: 4.493

4.  Methylenedioxy Piperamide-Derived Compound D5 Regulates Inflammatory Cytokine Secretion in a Culture of Human Glial Cells.

Authors:  Sajad Shahbazi; Tara Zakerali
Journal:  Molecules       Date:  2022-05-30       Impact factor: 4.927

5.  Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1-6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare.

Authors:  Nicola J Nasser; Kai Sun; Karen M Scanlon; Mark V Mishra; Jason K Molitoris
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

6.  Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer.

Authors:  Nicola J Nasser
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.575

Review 7.  Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor's Immune Environment.

Authors:  Aino Siltari; Heimo Syvälä; Yan-Ru Lou; Yuan Gao; Teemu J Murtola
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.